What are the clinical signs of Stevens‑Johnson syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 14, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Clinical Signs of Stevens-Johnson Syndrome

Stevens-Johnson syndrome presents with a characteristic triad: a prodrome of fever and malaise, followed by painful skin lesions with atypical flat targets or purpuric macules, and severe erosive mucositis affecting multiple sites (eyes, mouth, genitalia). 1

Prodromal Phase (Precedes Skin Eruption)

  • Fever, malaise, and upper respiratory tract symptoms typically occur several days before the rash appears 1
  • Severe cutaneous pain is a critical early warning sign that may precede visible skin changes and should immediately alert clinicians to incipient epidermal necrolysis 1, 2
  • Ocular inflammation may develop before any skin signs become apparent 1
  • Symptoms typically begin 4-28 days after drug exposure 3, 4

Cutaneous Manifestations

Initial Lesion Characteristics

  • Earliest lesions are atypical flat targets or purpuric macules with a dark-red center surrounded by a pink ring 1, 2
  • Initial distribution: upper torso, proximal limbs, and face, then spreads to trunk and distal extremities 1, 2
  • Palms and soles are frequently involved early in the disease course 1, 2

Progression Pattern

  • Lesions expand and coalesce, reaching maximum extent 5-7 days after disease onset 1, 2
  • Large areas of confluent erythema develop in severe cases 1
  • Affected skin is exquisitely tender to touch 1
  • Positive Nikolsky sign: gentle lateral pressure causes the epidermis to peel away from underlying dermis 1, 2
    • Caveat: This sign is helpful but not specific for SJS/TEN—it also occurs in pemphigus 1, 2

Advanced Skin Findings

  • Flaccid blisters form as necrotic epidermis separates from dermis 1
  • Sheet-like epidermal detachment exposes denuded dermis that exudes serum, bleeds readily, and is prone to secondary infection 1, 2

Mucosal Involvement (Usually an Early Feature)

  • Erosive and hemorrhagic mucositis affecting eyes, mouth, nose, and genitalia is typically present early 1, 2
  • Ocular signs: purulent keratoconjunctivitis, eyelid edema, and persistent inflammation 1, 5
  • Oral mucositis: erythema, blistering, and painful erosions 5
  • Genital involvement: pain and urinary retention 1
  • Important distinction: In Mycoplasma-associated cases, mucosal involvement may predominate with minimal cutaneous lesions 1, 2

Respiratory Manifestations

  • Cough, dyspnea, bronchial hypersecretion, and hemoptysis indicate respiratory tract involvement 1
  • Dyspnea occurs in approximately 25% of patients 5
  • Bronchial hypersecretion occurs in 70% of patients with early pulmonary manifestations 5

Gastrointestinal Signs

  • Diarrhea and abdominal distension suggest bowel involvement 1

Classification by Extent of Epidermal Detachment

  • SJS: <10% body surface area (BSA) detachment plus widespread purpuric macules or flat atypical targets 2, 6
  • SJS-TEN overlap: 10-30% BSA detachment 2, 6
  • TEN: >30% BSA detachment 2, 6

Critical Diagnostic Pitfalls to Avoid

  • Do not dismiss early cutaneous pain—this symptom preceding visible skin changes is a red-flag for incipient necrolysis 1, 2
  • Differentiate from erythema multiforme major: EMM has raised target lesions predominantly on limbs/extremities, whereas SJS has flat atypical targets more widely distributed 1, 2
  • Differentiate from staphylococcal scalded skin syndrome (SSSS): SSSS lacks mucosal involvement and shows intraepidermal (not subepidermal) cleavage on biopsy 1
  • Document both extent of erythema AND percentage of epidermal detachment, as detachable epidermis may initially appear as dusky erythema before frank blistering 2
  • Consider infectious triggers (HSV, Mycoplasma, Chlamydia) in addition to drugs, especially in children with predominant mucositis and limited skin involvement 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Clinical Characteristics

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update.

American journal of clinical dermatology, 2015

Guideline

Stevens-Johnson Syndrome: Clinical Presentation and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Clinical reviews in allergy & immunology, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.